Treatment of severe COVID-19 patients with either low- or high-volume of convalescent plasma versus standard of care: A multicenter Bayesian randomized open-label clinical trial (COOP-COVID-19-MCTI)
Alice T W Song, Vanderson Rocha, Alfredo Mendrone-Júnior, Rodrigo T Calado, Gil C De Santis, Bruno D Benites, Carolina Costa-Lima, Taiani Vargas, Leonardo S Marques, Juliana C Fernandes, Felipe C Breda, Silvano Wendel, Roberta Fachini, Luiz V Rizzo, José Mauro Kutner, Vivian I Avelino-Silva, Rafael R G Machado, Edison L Durigon, Sylvie Chevret, Esper G Kallas, Alice T W Song, Vanderson Rocha, Alfredo Mendrone-Júnior, Rodrigo T Calado, Gil C De Santis, Bruno D Benites, Carolina Costa-Lima, Taiani Vargas, Leonardo S Marques, Juliana C Fernandes, Felipe C Breda, Silvano Wendel, Roberta Fachini, Luiz V Rizzo, José Mauro Kutner, Vivian I Avelino-Silva, Rafael R G Machado, Edison L Durigon, Sylvie Chevret, Esper G Kallas
Abstract
Background: Administration of convalescent plasma may serve as an adjunct to supportive treatment to prevent COVID-19 progression and death. We aimed to evaluate the efficacy and safety of 2 volumes of intravenous convalescent plasma (CP) with high antibody titers for the treatment of severe cases of COVID-19.
Methods: We conducted a Bayesian, randomized, open-label, multicenter, controlled clinical trial in 7 Brazilian hospitals. Adults admitted to hospital with positive RT-PCR for SARS-CoV2, within 10 days of the symptom onset, were eligible. Patients were randomly assigned (1:1:1) to receive standard of care (SoC) alone, or in combination with 200 mL (150-300 mL) of CP (Low-volume), or 400 mL (300-600 mL) of CP (High-volume); infusion had to be performed within 24 h of randomization. Randomization was centralized, stratified by center. The primary outcome was the time until clinical improvement up to day 28, measured by the WHO ten-point scale, assessed in the intention-to-treat population. Interim and terminal analyses were performed in a Bayesian framework. Trial registered at ClinicalTrials.gov: NCT04415086.
Findings: Between June 2, 2020, and November 18, 2020, 129 patients were enrolled and randomly assigned to SoC (n = 42), Low-volume (n = 43) or High-volume (n = 44) CP. Donors presented a median titer of neutralizing antibodies of 1:320 (interquartile range, 1:160 to 1:1088). No evidence of any benefit of convalescent plasma was observed, with Bayesian estimate of 28-day clinical improvement of 72.7% (95%CI, 58.8 to 84.7) in the SoC versus 64.1% (95%ci, 53.8 to 73.7) in the pooled experimental groups (mean difference of -8.7%, 95%CI, -24.6 to 8.2). There was one case of cutaneous mild allergic reaction related to plasma transfusion and one case of suspected transfusion-related acute lung injury but deemed not to be related to convalescent plasma infusion.
Interpretation: In this prospective, randomized trial of adult hospitalized patients with severe COVID-19, convalescent plasma was not associated with clinical benefits.
Funding: Brazilian Ministry of Science, Technology and Innovation, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Keywords: COVID-19; Convalescent plasma; SARS-CoV-2.
Conflict of interest statement
Authors declare no competing interests.
© 2022 The Author(s).
Figures
References
- WHO Coronavirus (COVID-19) dashboard. Updated August 18, 2021. Available at .
- Joyner M.J., Carter R.E., Senefeld J.W., et al. Convalescent plasma antibody levels and the risk of death from Covid-19. N Engl J Med. 2021;384:1015–1027.
- Chen P., Nirula A., Heller B., et al. SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19. N Engl J Med. 2021;384:229–237.
- Weinreich D.M., Sivapalasingam S., Norton T., et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N Engl J Med. 2021;384:238–251.
- Cheng Y., Wong R., Soo Y.O.Y., et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005;24:44–46.
- Hung I.F., To K.K., Lee C.K., et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011;52:447–456.
- Hung I.F.N., To K.K.W., Lee C.K., et al. Hyperimmune IV immunoglobulin treatment. Chest. 2013;144:464–473.
- van Griensven J., Edwards T., de Lamballerie X., et al. Evaluation of convalescent plasma for Ebola virus disease in Guinea. N Engl J Med. 2016;374:33–42.
- Zhou B., Zhong N., Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450–1451.
- Food and Drug Administration (FDA). Recommendations for investigational COVID-19 convalescent plasma. Available at: . Accessed August 18, 2021.
- Ministério da Saúde, Agência Nacional de Vigilância Sanitária. Nota Técnica No 21/2020-CGSH/DAET/SAES/MS. Available at . Accessed September 10, 2021.
- Marshall J.C., Murthy S., Diaz J., et al. A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020;20:e192–e197.
- Working Party for Haemovigilance. International society of blood transfusion/internation haemovigilance network. Available at with the updated TACO definition at . Accessed April 20, 2020.
- Ryan E.G., Bruce J., Metcalfe A.J., et al. Using Bayesian adaptive designs to improve phase III trials: a respiratory care example. BMC Med Res Methodol. 2019;19 doi: 10.1186/s12874-019-0739-3. Epub ahead of print December.
- Berry DA. Bayesian clinical trials. Nat Rev Drug Discov. 2006;5:27–36.
- Harrell F., Lindsell C. Statistical design and analysis plan for sequential parallel-group RCT for COVID-19. Available at: . Accessed March 30, 2020.
- von Cube M., Schumacher M., Wolkewitz M. Causal inference with multistate models—estimands and estimators of the population attributable fraction. J R Stat Soc Ser A Stat Soc. 2020;183:1479–1500.
- Joyner M.J., Bruno K.A., Klassen S.A., et al. Safety update. Mayo Clin Proc. 2020;95:1888–1897.
- Salazar E., Christensen P.A., Graviss E.A., et al. Treatment of coronavirus disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190:2290–2303.
- Tworek A., Jaroń K., Uszyńska-Kałuża B., et al. Convalescent plasma treatment is associated with lower mortality and better outcomes in high-risk COVID-19 patients – propensity-score matched case-control study. Int J Infect Dis. 2021;105:209–215.
- Li L., Zhang W., Hu Y., et al. Effect of convalescent plasma therapy on time to clinical improvement in patients with severe and life-threatening COVID-19: a randomized clinical trial. JAMA. 2020;324:460.
- Gharbharan A., Jordans C.C.E., GeurtsvanKessel C., et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12:3189.
- Simonovich V.A., Burgos Pratx L.D., Scibona P., et al. A Randomized trial of convalescent plasma in Covid-19 severe pneumonia. N Engl J Med. 2021;384:619–629.
- Menichetti F., Popoli P., Puopolo M., et al. Effect of high-titer convalescent plasma on progression to severe respiratory failure or death in hospitalized patients with COVID-19 pneumonia: a randomized clinical trial. JAMA Netw Open. 2021;4
- Abani O., Abbas A., Abbas F., et al. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. The Lancet. 2021;397:2049–2059.
- Sekine L., Arns B., Fabro B.R., et al. Convalescent plasma for COVID-19 in hospitalised patients: an open-label, randomised clinical trial. Eur Respir J. 2021
- Bégin P., Callum J., Jamula E., et al. Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial. Nat Med. 2021 doi: 10.1038/s41591-021-01488-2. Epub ahead of print.
- Körper S., Weiss M., Zickler D., et al. Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19. J Clin Invest. 2021;131
- O'Donnell M.R., Grinsztejn B., Cummings M.J., et al. A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19. J Clin Invest. 2021;131
- Korley F.K., Durkalski-Mauldin V., Yeatts S.D., et al. Early convalescent plasma for high-risk outpatients with Covid-19. N Engl J Med. 2021 NEJMoa2103784.
- Libster R., Pérez Marc G., Wappner D., et al. Early high-titer plasma therapy to prevent severe Covid-19 in older adults. N Engl J Med. 2021;384:610–618.
- Hamilton F.W., Lee T., Arnold D.T., et al. Is convalescent plasma futile in COVID-19? A Bayesian re-analysis of the RECOVERY randomized controlled trial. Int J Infect Dis. 2021;109:114–117.
- Avendaño-Solá C., Ramos-Martínez A., Muñez-Rubio E., et al. A multicenter randomized open-label clinical trial for convalescent plasma in patients hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131
- Bar K.J., Shaw P.A., Choi G.H., et al. A randomized controlled study of convalescent plasma for individuals hospitalized with COVID-19 pneumonia. J Clin Invest. 2021;131
- Kunze K.L., Johnson P.W., van Helmond N., et al. Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors. Nat Commun. 2021;12:4864.
- Horby PW, Mafham M, RECOVERY Collaborative Group, Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Preprint, Infectious Diseases (except HIV/AIDS). Epub ahead of print, 16 June 2021. DOI:10.1101/2021.06.15.21258542
- Casadevall A., Henderson J.P., Joyner M.J., et al. SARS-CoV-2 variants and convalescent plasma: reality, fallacies, and opportunities. J Clin Invest. 2021;131
- Matthay M.A., Thompson B.T. Dexamethasone in hospitalised patients with COVID-19: addressing uncertainties. Lancet Respir Med. 2020;8:1170–1172.
Source: PubMed